Clinical experience with infliximab therapy in 100 patients with Crohn's disease

American Journal of Gastroenterology

Volumn 95, Issue 12, 2000, Pages 3490-3497

  Farrell, Richard J ^a   Shah, Samir A ^b   Lodhavia, Parag J ^b   Alsahli, Mazen ^b   Falchuk, Kenneth R ^b   Michetti, Pierre ^b   Peppercorn, Mark A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; STEROID;

ADOLESCENT; ADULT; AGED; ANAPHYLACTIC SHOCK; ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; PREDNISONE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0033639123     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)02159-6     Document Type: Article

References (15)

1. Tumour necrosis factor and Crohn's disease
2. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
3. Infliximab for the treatment of fistulas in patients with Crohn's disease
4. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease
5. A simple index of Crohn's-disease activity
6. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group
7. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group
8. A randomized double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent disease
9. Infliximab in Crohn's disease: First anniversary clinical experience
10. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
11. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis
12. The influence of TNF mAB, cA2, on circulating lymphocyte populations
13. Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis
14. Therapy of inflammatory bowel disease